[12] Patent
[11] Patent No.:GC0004521  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2016                32/2016  
Number of the Decision to Grant the Patent:2016/89559
Date of the Decision to Grant the Patent:14/Dec/2016

[21] Application No.:GC 2011-17921

[22] Filing Date:8/3/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.

[72] Inventors:1- PRASAD, Leena،2- MILLER, Jonathan،3- SCHMITT, Eric A.،4- GOKHALE, Rajeev،5- MORRIS, John B.،6- ROSENBLATT, Karin،7- HOLIG, Peter،8- LIEPOLD, Bernd،9- Gerd Woehrle

[73] Owner: AbbVie Ireland Unlimited company, Clarendon house, 2 Church street , Hamilton, Bermuda

[74] Agent: Suleiman I. Al-Ammar Law Office




Int. Cl.: A61K 31/395, 31/4965, 31/498, 47/30, 9/20; A61P 31/14 (2006.01)

[56] Cited Documents:

-US 2010-0144608 A1 (YIYIN KU et al.) 10 June 2010
-US 2010-0168384 A1 (KEITH F. MCDANIEL et a1.) 01 July 2010
-US 2009-0269305 A1 (SCOTT D. SETWERT et a1.) 29 October 2009
-US 2004-0229776 A1 (SHIRLYNN CHEN et a1.) 18 November 2004
-US 2003-0195228 A1 (SHIRLYNN CHEN et al.) 16 October 2008
Examiner: PH. Nada A. AlShamrani

[57] Abstract: The present invention features solid compositions comprising amorphous Compound I. A solid dispersion of the present invention also contains a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant. Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
No. of claims: 20


Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.